(1.20%) 5 124.91 points
(1.16%) 38 670 points
(1.92%) 16 144 points
(-0.68%) $78.41
(5.21%) $2.14
(-0.13%) $2 306.70
(-0.46%) $26.71
(0.34%) $965.85
(-0.36%) $0.929
(-1.17%) $10.86
(-0.11%) $0.797
(0.36%) $91.46
1.24% ¥ 409.00
Live Chart Being Loaded With Signals
Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide...
Stats | |
---|---|
Dzisiejszy wolumen | 31 300.00 |
Średni wolumen | 104 916 |
Kapitalizacja rynkowa | 9.24B |
EPS | ¥0 ( 2024-02-13 ) |
Następna data zysków | ( ¥0 ) 2024-05-12 |
Last Dividend | ¥14.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 13.41 |
ATR14 | ¥1.087 (0.27%) |
Linical Co., Ltd. Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Linical Co., Ltd. Finanse
Annual | 2022 |
Przychody: | ¥12.52B |
Zysk brutto: | ¥4.16B (33.25 %) |
EPS: | ¥44.47 |
FY | 2022 |
Przychody: | ¥12.52B |
Zysk brutto: | ¥4.16B (33.25 %) |
EPS: | ¥44.47 |
FY | 2022 |
Przychody: | ¥11.56B |
Zysk brutto: | ¥3.61B (31.26 %) |
EPS: | ¥35.00 |
FY | 2021 |
Przychody: | ¥10.28B |
Zysk brutto: | ¥2.77B (26.92 %) |
EPS: | ¥23.91 |
Financial Reports:
No articles found.
Linical Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥0 (N/A) |
¥14.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥3.00 | 2009-03-26 |
Last Dividend | ¥14.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 16 | -- |
Total Paid Out | ¥111.75 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.77 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 3.06 | |
Div. Directional Score | 7.05 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8377.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
7775.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6941.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6301.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5020.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4224.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
3443.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
2587.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
9303.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8101.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0543 | 1.500 | 8.91 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0385 | 1.200 | 8.72 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0876 | 1.500 | -0.138 | -0.206 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.712 | 0.800 | 6.44 | 5.15 | [1 - 3] |
quickRatioTTM | 1.467 | 0.800 | 6.08 | 4.86 | [0.8 - 2.5] |
cashRatioTTM | 1.018 | 1.500 | 5.46 | 8.19 | [0.2 - 2] |
debtRatioTTM | 0.154 | -1.500 | 7.43 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 71.54 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 44.92 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 44.92 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.349 | -1.500 | 8.60 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.324 | 1.000 | 7.93 | 7.93 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0925 | 1.000 | -0.151 | -0.151 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.372 | 1.000 | 9.05 | 9.05 | [0.2 - 2] |
assetTurnoverTTM | 0.708 | 0.800 | 8.61 | 6.89 | [0.5 - 2] |
Total Score | 11.04 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 13.58 | 1.000 | 8.73 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0876 | 2.50 | -0.0884 | -0.206 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 44.92 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.67 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 44.92 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.242 | 1.500 | -4.95 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0810 | 1.000 | -0.474 | 0 | [0.1 - 0.5] |
Total Score | 3.06 |
Linical Co., Ltd.
Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs consultation support, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariat; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej